- BYND Cannasoft Enterprises (CSE:BYND) is focusing its work to meet the increased demand for medical cannabis in Israel
- Israel has reported a significant increase in the number of licensed medical cannabis patients in the wake of recent events, particularly the opening of the war in Gaza
- This surge has created more than 2,000 new patients in just one month, approaching the peak numbers of 2021 and bringing the total number to more than 132,000 as of November 2023
- BYND Cannasoft Enterprises Inc. last traded at C$1.05 per share
BYND Cannasoft Enterprises (CSE:BYND) is focusing its work to meet the increased demand for medical cannabis in Israel.
Israel has reported a significant increase in the number of licensed medical cannabis patients in the wake of recent events, particularly the opening of the war in Gaza. This surge has created more than 2,000 new patients in just one month, approaching the peak numbers of 2021 and bringing the total number to more than 132,000 as of November 2023.
Many of the medical cannabis patients receiving new licenses are war casualties, as doctors began issuing licenses for post-trauma to victims of the recent events. In terms of patient age, more than 60,000 medical cannabis patients in Israel, nearly half of the total, fall in the 21 to 45 age range.
According to cannabis news outlet Norml, the Israeli Ministry of Health recently approved regulatory reforms that allow physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.
BYND Cannasoft’s Benefit CRM is a proprietary customer relationship management software product. It enables small and medium-sized enterprises to optimize day-to-day functions such as sales management, workforce management, contact centre operations, and asset management. Benefit CRM is provisioned as software-as-a-service (SaaS) to some of Israel’s most recognizable companies.
As part of the new plan of work, the team said its software development phase will focus on innovative elements in the field of artificial intelligence that will increase their data collection and analysis.
“Israel is a small country, and although we continue to take a business-as-usual approach, every one of us is directly impacted, either personally or through our family and loved ones. BYND Cannasoft supports and stands with all of the Israelis affected by this tragedy. In Israel, the cannabis and pharmaceuticals industries are part of the critical infrastructure sector, and I am very proud of how the team is coming together to work through this horrific situation,” Yftah Ben Yaackov, CEO and director of BYND, said in a statement. “While we continue to develop our EZ-G device for the recreational market, and potentially as an FDA-approved medical device, our decision to refocus on cannabis will benefit our shareholders, as well as those impacted by the war who are seeking treatment from psychiatric and pain clinics. We are grateful to be in this position to help our country and its people.”
BYND is an Israeli-based integrated software and cannabis company.
BYND Cannasoft Enterprises Inc. last traded at C$1.05 per share.
Join the discussion: Find out what everybody’s saying about this stock on the BYND Cannasoft Enterprises stock forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
